When Will Vonoprazan Go Generic?
The patent expiry for vonoprazan, a potassium-competitive acid blocker, is a key factor in its generic availability. While specific patent expiration dates can be complex and subject to various legal challenges and extensions, information from sources like DrugPatentWatch.com can provide insights into potential timelines for generic entry. [1]
What is Vonoprazan Used For?
Vonoprazan is a medication used to treat acid-related disorders. It works by inhibiting the proton pump in the stomach, thereby reducing acid production. This makes it effective for conditions such as erosive esophagitis, gastric ulcers, duodenal ulcers, and as part of treatment regimens for Helicobacter pylori infection. [2]
How Does Vonoprazan Work?
Unlike proton pump inhibitors (PPIs) that require activation in an acidic environment, vonoprazan is a potassium-competitive acid blocker (P-CAB). It directly binds to the H+/K+-ATPase enzyme (the proton pump) in a reversible, potassium-competitive manner. This mechanism leads to rapid and sustained suppression of gastric acid secretion. [3]
What Are the Potential Side Effects of Vonoprazan?
Common side effects associated with vonoprazan may include diarrhea, constipation, nausea, abdominal pain, and headache. Less common side effects can also occur. It is important for patients to discuss any concerns with their healthcare provider. [4]
Can Biosimilars Be Developed for Vonoprazan?
Vonoprazan is a small molecule drug, not a biologic. Therefore, the term "biosimilar" does not apply. Instead, generic versions of vonoprazan, which are chemically identical to the original drug, are what would become available after patent protections expire. [5]
Who Developed Vonoprazan and Who Manufactures It?
Vonoprazan was developed by Takeda Pharmaceutical Company. It is marketed under brand names such as Takecab and Voquezna. [2]
What Is the Difference Between Vonoprazan and Proton Pump Inhibitors (PPIs)?
The primary difference lies in their mechanism of action and onset of effect. Vonoprazan, as a P-CAB, offers a different mechanism for acid suppression compared to traditional PPIs like omeprazole or pantoprazole. P-CABs like vonoprazan are known for their rapid onset of action and potent, sustained acid suppression. [3]